Skip to main content

Albiglutide

Heart and stethoscope

08-19-2019 | GLP-1 agonists | Highlight | News

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

Heart and ECG_Fotolia_287046_Subscription_XL

10-02-2018 | Albiglutide | EASD 2018 | News

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.